Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression
|
|
- Douglas Kennedy
- 5 years ago
- Views:
Transcription
1 Original article Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression Peter Birner 1, Kalina Toumangelova-Uzeir 2, Sevdalin Natchev 2, Marin Guentchev 3 1Institute of Neurology and Comprehensive Cancer Center, CNS-Unit, Medical University of Vienna, Währinger Gürtel, Vienna, Austria, 2Laboratory of Neuropathology, St. Ivan Rilsky Hospital, 15, Akad. I. Geschov Blvd., Sofia, Bulgaria, 3 Department of Neurosurgery, Pirogov Emergency Hospital, 21, General Eduard Totleben Blvd., Sofia, Bulgaria Folia Neuropathol 2011; 49 (2): Abstract Gliomas are the most common primary brain tumours. Several independent studies have shown that isocitrate dehydrogenase 1 (IDH1) mutation in diffuse gliomas is associated with a more favourable patient outcome. The aim of this study was to evaluate the prognostic relevance of an antibody specifically detecting the R132H point mutation of IDH1 in tissue sections in a large series of human gliomas. Surgical specimens of 220 consecutive patients with infiltrative low and high-grade gliomas were included in this retrospective study. In multivariate analysis, IDH expression did not reach significance (p = 0.122) in regard to prognosis, in contrast to WHO grade and age at time of surgery (p < 0.001, Cox regression). A significant correlation of p53 expression to mutated IDH1 and histological grading and an inverse correlation to truncated EGFR expression were observed (p < 0.001, Mann-Whitney test). In sum, our results indicate that IDH R132H mutation correlates significantly with p53 and inversely with EGFR mutations. Further studies should investigate whether these correlations reflect involvement of these three molecules in a common signalling pathway. Key words: gliomas, isocitrate dehydrogenase 1 mutation, p53 expression, EGFR expression. Introduction Gliomas are the most common primary brain tumours [11]. Recent genome-wide mutational analysis has demonstrated that 12% of glioblastomas (GBM) harbour mutations of the cytosolic NADP + - dependent isocitrate dehydrogenase (IDH) gene [15], an enzyme involved in isocitrate oxidative decarboxylation. Most GBM mutations replace arginine in position 132 with histidine (R132H), thus producing a do - minant-negative form of the protein [15,19]. IDH1 mutations were more frequent in secondary GBM [1,8,9,15,16], anaplastic astrocytomas, and grade II gliomas [1,8,9,16,17]. By contrast, IDH1 mutations have only been found in a few types of other CNS tumours. Communicating author: Marin Guentchev, Department of Neurosurgery, Pirogov Emergency Hospital, 21, Gen. Eduard Totleben Blvd, BG-1606, Sofia, Bulgaria, guentchev@gmail.com 88 Folia Neuropathologica 2011; 49/2
2 Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression IDH1 and IDH2 mutations are found in both astrocytomas and oligodendrogliomas, but accompanying genetic alterations differ. Most low-grade diffuse astrocytomas have both p53 and IDH1 mutations, whereas most oligodendrogliomas show both IDH1 mutations and chromosome 1p/19q co-deletion [17]. In several studies it has been demonstrated that an IDH1 mutation is associated with good prognosis in patients with gliomas [15,16,18]. Median overall survival in GBM patients with IDH mutations was significantly longer than that in GBM patients with wildtype IDH1 and IDH2 [15]. Mutations of IDH have also been shown to be associated with improved prognosis in patients with anaplastic astrocytomas [15,16]. Furthermore, immunohistochemical detection of IDH expression is considered as a very useful tumour cell marker in gliomas with an IDH mutation [5]. Recently, an antibody specifically detecting the R132H point mutation of IDH1 in tissue sections has become available [7]. The aim of this study was to evaluate the prognostic relevance of this IDH mutation assessed by this antibody in a large consecutive series of low- and high-grade human gliomas. Material and methods Surgical specimens of 220 patients used previo - usly [3,12] with low- and high-grade infiltrative glio - mas were included in this retrospective study. These patients comprised all glioma cases treated in the pe - riod from July 2004 to February 2008 at St. Ivan Rilski University Hospital. In all patients with glioblastoma, there was no clinical history of a preceding glioma with higher differentiation. Standard post operative adjuvant radiotherapy (50-60 Gy) was applied to all patients with grade III and grade IV glioma, representing the standard adjuvant therapy in Bulgaria in the given period. One hundred and five patients (47.7%) were female, 115 (52.3%) were male. Mean age of patients was 52.9 ± 13.8 years. One hundred and forty-five (65.9%) patients were classified as WHO grade IV, 32 patients (14.5%) as WHO grade III, and 43 (19.6%) as grade II. In addition, from 6 patients (4 with grade II glioma, 2 with grade III) tissue from subsequent secondary glioblastomas was available. Mean observation time was 978 ± 59 days (standard error). During this period 9 patients (20.9%) with initial grade II glioma, 21 (65.6%) with initial grade III glioma and 127 (87.6%) with glioblastoma died of their brain tumour. Immunohistochemistry Expression of IDH, p53 and EGFR was determined immunohistochemically in paraffin-embedded, para - formaldehyde-fixed specimens. Tissue microarrays (TMA) with fourteen 5 mm diameter samples per slide were used in this study. Histological slides, 4 μm in thickness, were deparaffinized in xylol. En - do genous peroxidase was blocked with methanol containing 0.3% hydrogen peroxide for 30 min. The following antibodies were used: mouse mono - clonal anti-human IDH1 R132H antibody (Dianova, clone H09, 1 : 10, 1 h at room temperature [RT]), mouse monoclonal anti-human p53 (Dako, clone DO-7, 1 : 50, 25 min at RT), mouse monoclonal binding to the type III truncated form of epidermal growth factor receptor (EGFR) without cross-reacting with the wild-type form (Novocastra, clone DH8.3, 1 : 100, 4 C overnight). The affinity-purified anti-idh antibody reacts specifically with the IDH1 R132H point mutation in tissue sections from formalin-fixed brain tumour specimens [4,6,8]. A specimen was considered as positive for mu - tated IDH expression if the vast majority of glioma cells (> 80%) showed strong cytoplasmic and nuclear (Figs. 1A and B) staining, positive for p53 expression if strong nuclear staining was present (Figs. 1C and D), and positive for EGFR expression if strong cytopla smic immunostaining (Figs. 1E and F) was observed. Statistics Chi-square test and Mann-Whitney test were used as appropriate. Overall survival was defined as the period from primary surgery until the death of the patient. Deaths from a cause other than glioma and survival until the end of the observation period were considered censored observations. Univariate analysis of overall survival was performed by Kaplan and Meier analysis or univariate Cox regression. Multivariate analysis of survival was performed by the Cox proportional hazards model. SPSS 17.0 (SPSS Inc., Chicago, IL) was used for all calculations. For all tests, a two-tailed p 0.05 was considered as signi - ficant. Numbers given are mean values ± standard deviation, if not stated otherwise. Folia Neuropathologica 2011; 49/2 89
3 Peter Birner, Kalina Toumangelova-Uzeir, Sevdalin Natchev, Marin Guentchev A B C D E F Fig. 1. Glioma specimens considered as positive (A) and negative (B) for IDH1 expression. Glioma specimens considered as positive (C) and negative (D) for p53 expression. Glioma specimens considered as positive (E) and negative (F) for EGFR expression. Immunoperoxidase. Scale bar = 100 μm. 90 Folia Neuropathologica 2011; 49/2
4 Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression Results IDH The results of immunohistochemistry are summarised in Table I. Fifty-one cases (23.72%) were positive for IDH R132H (Fig. 1). Half of the histologically proven secondary glioblastomas were IDH R132H positive (n = 3 out of 6 cases). Patients with mutated IDH positive tumours were significantly younger than those with mutated IDH negative ones (p < 0.001, Mann-Whitney test, mean age 45.3 ± 13.8 vs ± 13 years). Mean survival of wild type IDH (IDH wt ) GBM cases was 342 days and 326 in IDH R132H cases. Mean survival of IDH R132H glioma grade III cases was 773 days while IDH wt cases survived 597 days. None of the above differences showed statistical significance. In univariate analysis, IDH R132H -positive tumours had a significantly better survival (p = 0.023, log rank test) (Fig. 2). In multivariate analysis, IDH expression did not reach significance (p = 0.122) in regard to prognosis, in contrast to WHO grade and age at time of surgery (p < 0.001, Cox regression). No significant influence of IDH status on survival was also seen when investigating grade II, III and IV gliomas separately (p > 0.05, Cox regression). p53 Also patients with p53 positive tumours were younger than those with negative ones (p = 0.013, Mann-Whitney test, 48.8 ± 15.2 vs. 54 ± 13.2), while patients with EGFR expression were significantly older (p < 0.001, Mann-Whitney test, 59.8 ± 9.2 vs ± 14.3). No association of p53 expression with histological grading (p > 0.05, Mann-Whitney test) and EGFR expression (p > 0.05, Chi square test) was observed. A significant correlation to IDH status and histological grading was observed (p < 0.001, Mann- Whitney test): Median histological grading was III in IDH R132H positive cases, while it was grade IV in IDH negative gliomas. A significant association of IDH and p53 expression was found (p < 0.001, Chi square test): In the subgroup of 169 IDH wt cases, p53 positivity was seen in 25 cases (14.8%), while in the subgroup of 51 cases expressing IDH R132H, p53 positivity was seen in 21 (41.2%) cases. Interestingly, in p53 positive tumours, all IDH positive cases (n = 21) were negative for EGFR expression. EGFR Although the median histological grading was IV in both EGFR negative and positive tumours, there was a significant association of EGFR positivity with higher grade gliomas (p = 0.027, Mann-Whitney test). A reverse association of IDH and EGFR expression was observed (p < 0.001, Chi square test). In the subgroup of 51 IDH R132H positive cases only 2 cases (3.9%) expressed EGFR, while in the subgroup of 168 IDH wt cases 46 (27.4%) showed EGFR expression. (Only 219 cases were investigated for EGFR expression, since no material was left in one case.) Cumulative overall survival Time since surgery (days) Fig. 2. Cumulative overall survival of patients (n = 220). Dotted line shows survival of patients with expression of IDH R132H, full line survival of patients without IDH expression. Table I. Results of immunostaining All cases (n = 220) IDH+ p53+ EGFR+* WHO grade II (n = 43) 24 (55.8%) 11 (25.6%) 3 (7%) WHO grade III (n = 32) 7 (21.9%) 8 (25%) 8 (25%) WHO grade IV (n = 145) 20 (13.8%) 27 (18.6%) 37 (25.5%)* *No tissue left for EGFR staining in one case Folia Neuropathologica 2011; 49/2 91
5 Peter Birner, Kalina Toumangelova-Uzeir, Sevdalin Natchev, Marin Guentchev Discussion Several studies have shown that IDH1 mutation is an independent favourable prognostic marker in GBM and anaplastic gliomas after adjustment for other genomic profiles and treatment modality [13,15,19]. In contrast to those reports, the results in our consecutive series of glioma patients show that expression of mutant IDH is not an independent prognostic factor. There are several possible explanations for this discrepancy. Most other studies have used DNA sequencing to detect IDH mutations. In our study an immunohistochemical method was used to detect mutant IDH R132H, which may result in a different rate of detection of IDH mutations compared to sequencing. This explanation seems unlikely since the immu - nohistochemical approach has been shown to perfectly match the results of direct sequencing of IDH1 codon R132H with a sensitivity of 94% and a specificity of 100% [6]. Another possible explanation is the fact that most studies have investigated the prognostic sum effect of several mutations of the IDH gene R132H, R132C, R132S, R132L, and R132G. Our study however investigated only R132H, which is the most common mutation. Thus in our study all other mutations, R132C, R132S, R132L, and R132G, comprising 12% of all IDH mutations [13], were not identified and so were included in the IDH wt group. The presence of other IDH mutations in the control group might distort the significance. Furthermore, our study shows that IDH R132H mutation correlates significantly with p53 accumulation and is in a reverse correlation to EGFR expression. Increased expression of p53 most likely reflects the presence of loss of function mutations in the protein [10]. Mutations of the p53 gene are most commonly found in low-grade gliomas and younger pa - tients [14]. Previous reports of our group have shown that glioblastoma patients with immunohistochemically detectable p53 protein expression had significantly better overall survival [2], but our current study investigating a different set of patients was not able to confirm these findings. The discrepancy could be explained by the different treatment modalities of the patient groups, since most of our pa - tients did not receive chemotherapy, contrary to the patient group in the previous report [2]. To our knowledge, no data indicating a functional relationship between IDH and p53 or EGFR exist. Since our study revealed strong correlations bet - ween IDH and p53 as well as EGFR protein expression levels, potential interactions between these genes in human gliomas deserve further investigations. In sum, our results indicate that IDH R132H mutation correlates significantly with p53 and inversely with EGFR mutations. Further studies should investigate whether these correlations reflect involvement of these three molecules in a common signalling pathway. Acknowledgments The authors are grateful to Dr. Johannes Hainfellner, Vienna, for advice and critical discussions. This work was supported by European Union Social Fund Program BG051PO001/07/ grant number 80/ and BSF grant number L01-840/ References 1. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ungersböck K, Rössler K, Budka H, Hainfellner JA. Prognostic relevance of p53 protein expression in glioblastoma. Oncol Rep 2002; 9: Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M. STAT3 tyrosine phosphorylation influences survival in glio - blastoma. J Neurooncol 2010; 100: Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendrogliomalike morphology. Acta Neuropathol 2011; 121: Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010; 34: Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20: Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118: Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold- Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenber - ger G, von Deimling A. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial dif- 92 Folia Neuropathologica 2011; 49/2
6 Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression ferentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118: Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology 2009; 11: Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, Herbst F, Teleky B, Wrba F. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer. J Pathol 2000; 190: Louis D, International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. 4th ed. International Agency for Research on Cancer, Lyon Maresch J, Birner P, Zakharinov M, Toumangelova-Uzeir K, Natchev S, Guentchev M. Additive effect on survival of Raf kinase inhibitor protein and signal transducer and activator of transcription 3 in high-grade glioma. Cancer 2011 (in press) 13. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 2009; 100: Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: Folia Neuropathologica 2011; 49/2 93
IDH-1 R132H mutation status in diffuse glioma patients: implications for classification
/, Advance Publications 2016 IDH-1 R132H mutation status in diffuse glioma patients: implications for classification Peng-fei Wang 1,*, Ning Liu 1,*, Hong-wang Song 1, Kun Yao 2, Tao Jiang 1,3,4,5,**,
More informationDetection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
DOI.7/s4--3-7 ORIGINAL ARTICLE Detection of IDH mutation in human gliomas: comparison of immunohistochemistry and sequencing Shingo Takano Wei Tian Masahide Matsuda Tetsuya Yamamoto Eiichi Ishikawa Mika
More informationThe New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
More informationCase Report IDH1 R132H mutation in a pilocytic astrocytoma: a case report
Int J Clin Exp Pathol 2015;8(9):11809-11813 www.ijcep.com /ISSN:1936-2625/IJCEP0012939 Case Report IDH1 R132H mutation in a pilocytic astrocytoma: a case report Felix Behling 1, Julia Steinhilber 2, Marcos
More informationImmunohistochemical Classification of Primary and Secondary Glioblastomas
The Korean Journal of Pathology 2013; 47: 541-548 ORIGINAL ARTICLE Immunohistochemical Classification of Primary and Secondary Glioblastomas Kyu Sang Lee Gheeyoung Choe 1 Kyung Han Nam 1 An Na Seo 1 Sumi
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationCharacterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence
DOI 10.1007/s10014-013-0172-y ORIGINAL ARTICLE Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence Hemragul Sabit Mitsutoshi Nakada Takuya Furuta Takuya Watanabe Yutaka
More informationAssociation between IDH1/2 mutations and brain glioma grade
ONCOLOGY LETTERS Association between IDH1/2 mutations and brain glioma grade LEI DENG 1, PENGJU XIONG 2, YUNHUI LUO 2, XIAO BU 2, SUOKAI QIAN 2, WUZHAO ZHONG 2 and SHUNQING LV 3 1 Department of Neurosurgery,
More informationAnalysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas
Neuro-Oncology Neuro-Oncology 16(7), 914 923, 2014 doi:10.1093/neuonc/not299 Advance Access date 26 January 2014 Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical
More informationTERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas
/, Vol. 6, No. 28 TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas Zhen-Yu Zhang 1,*, Aden Ka-Yin Chan
More informationMorphological features and genetic alterations
Morphological features and genetic alterations Tutor : Audrey Rousseau Caget Lise: Université d Angers Iorio Vittoria: Seconda Università degli studi di Napoli Manaila Roxana: Iuliu Hatieganu University
More informationPrognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2013 Prognostic or predictive value of MGMT promoter methylation in gliomas
More informationIDH1 Mutation in Gliomas in Baghdad by Immunohistochemical Study
International Journal of Genetics and Genomics 2018; 6(1): 1-7 http://www.sciencepublishinggroup.com/j/ijgg doi: 10.11648/j.ijgg.20180601.11 ISSN: 2376-7340 (Print); ISSN: 2376-7359 (Online) IDH1 Mutation
More informationIntegrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community
Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community The Harvard community has made this article openly available. Please
More informationA Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples
Journal of Molecular Diagnostics, Vol. 12, No. 6, November 2010 Copyright American Society for Investigative Pathology and the Association for Molecular Pathology DOI: 10.2353/jmoldx.2010.090237 A Pyrosequencing-Based
More informationIDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta- Analysis
IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta- Analysis Peng Zou 1, Haitao Xu 1, Pin Chen 1, Qing Yan 1, Lin Zhao 1, Peng Zhao 1 *, Aihua Gu 2 * 1 Department
More informationResearch Article The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas
The Scientific World Journal Volume 2013, Article ID 403942, 4 pages http://dx.doi.org/10.1155/2013/403942 Research Article The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationIDH1 mutation of gliomas with long-term survival analysis
ONCOLOGY REPORTS 28: 1639-1644, 2012 IDH1 mutation of gliomas with long-term survival analysis JAE KYUNG MYUNG 1, HWA JIN CHO 1, CHUL-KEE PARK 3, SEUNG-KI KIM 4, JI HOON PHI 4 and SUNG-HYE PARK 1,2 1 Department
More information5-hydroxymethylcytosine loss is associated with poor prognosis for
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas Feng Zhang 1,*, Yifan Liu 2, Zhiwen Zhang 1, Jie Li 1, Yi Wan 3, Liying Zhang 1, Yangmei
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationPr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille
Novelties in the WHO 2016 classification of brain tumours Pr D.Figarella-Branger Service d Anatomie Pathologique et de Neuropathologie, La Timone, Marseille UMR 911 Inserm, Université d Aix-Marseille The
More informationATRX loss refines the classification of anaplastic gliomas and identifies a. subgroup of IDH mutant astrocytic tumors with better prognosis
Wiestler et al. 1 ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis Benedikt Wiestler 1,4, David Capper 2,5, Tim
More informationClinical significance of genetic analysis in glioblastoma treatment
Clinical significance of genetic analysis in glioblastoma treatment Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Koji Yoshimoto Can we get prognostic
More informationDetection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies
Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies Journal of Molecular Diagnostics, Vol. 12, No. 4, July 2010 Copyright American Society
More informationIDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Neuro-Oncology Neuro-Oncology 16(1), 81 91, 2014 doi:10.1093/neuonc/not159 Advance Access date 4 December 2013 IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationGlioblastoma with Oligodendroglioma Component (GBM-O): Molecular Genetic and Clinical Characteristics
Glioblastoma with Oligodendroglioma Component (GBM-O): Molecular Genetic and Clinical Characteristics Christina L. Appin, Emory University Jingjing Gao, Emory University Candace Chisolm, Emory University
More informationGliomas in the 2016 WHO Classification of CNS Tumors
Gliomas in the 2016 WHO Classification of CNS Tumors Hindi N Al-Hindi, MD, FCAP Consultant Neuropathologist and Head Section of Anatomic Pathology Department of Pathology and Laboratory Medicine King Faisal
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationCOLD-PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR IDH1 MUTATION
COLD-PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR IDH MUTATION Blandine Boisselier, Yannick Marie, Marianne Labussière, Pietro Ciccarino, Virginie Desestret, Xiaowei Wang, Laurent Capelle, Jean-Yves
More informationResearch Article Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
BioMed Research International, Article ID 735659, 5 pages http://dx.doi.org/10.1155/2014/735659 Research Article Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme
More informationSupplemental Information. Molecular, Pathological, Radiological, and Immune. Profiling of Non-brainstem Pediatric High-Grade
Cancer Cell, Volume 33 Supplemental Information Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial Alan Mackay,
More informationDiagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 1 Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants Nancy M Joseph 1, Joanna Phillips
More informationIDH1 and IDH2 Mutations in Gliomas
The new england journal of medicine original article 1 and Mutations in Gliomas ai Yan, M.D., Ph.D., D. Williams Parsons, M.D., Ph.D., Genglin Jin, Ph.D., Roger McLendon, M.D., B. Ahmed Rasheed, Ph.D.,
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationNature Genetics: doi: /ng.2995
Supplementary Figure 1 Kaplan-Meier survival curves of patients with brainstem tumors. (a) Comparison of patients with PPM1D mutation versus wild-type PPM1D. (b) Comparison of patients with PPM1D mutation
More informationDual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?
Journal of Neuropatholgy & Experimental Neurology Vol. 0, No. 0, 2017, pp. 1 5 doi: 10.1093/jnen/nlx024 BRIEF REPORT Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationClassification of Diffuse Gliomas: Progress, Pearls and Pitfalls. Rob Macaulay Neuropathologist, MCC October 21, 2017
Classification of Diffuse Gliomas: Progress, Pearls and Pitfalls Rob Macaulay Neuropathologist, MCC October 21, 2017 Objectives Explain why the designation high grade glioma is preferable to GBM for intraoperative
More informationDisclaimers. Molecular pathology of brain tumors. Some aspects only. Some details are inevitably personal opinions
Molecular pathology of brain tumors Disclaimers Some aspects only H.K. Ng The Chinese University of Hong Kong Some details are inevitably personal opinions Free ppt : http://www.acp.cuhk.edu.hk/hkng Why
More informationYeni Yuzyil University, Medical Faculty, Gaziosmanpasa Hospital, Department of Pathology, Istanbul, Turkey 2
DOI: 10.5137/1019-5149.JTN.16832-15.1 Received: 22.12.2015 / Accepted: 05.08.2016 Published Online: 19.09.2016 Original Investigation The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression
More informationA new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
DOI 10.1007/s11060-012-1026-x CLINICAL STUDY A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors Haihui Jiang Xiaohui Ren Wei Zhang Jun Ma Dali
More informationATRX and IDH1 R132H immunohistochemistry with subsequent copy number analysis and IDH
Acta Neuropathol (2015) 129:133 146 DOI 10.1007/s00401-014-1370-3 ORIGINAL PAPER ATRX and IDH1 R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated
More informationR1601 Essential Immunohistochemical and Molecular Markers for General CNS Glial Tumors
October 22, 2018 12:00-1:00 PM Background The World Health Organization Classification of tumors of the Central Nervous System has recently been revised. There is now greater emphasis on molecular phenotype
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationUNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT?
UNDERSTANDING MOLECULAR TESTING IN BRAIN TUMORS: HOW CLINICALLY USEFUL IS IT? Seema Nagpal, MD Stanford University Stanford, CA Goals: 1. Describe the most commonly used tests in glioma, including MGMT,
More informationATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
, Vol. 3 (7-8), July 2016 ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors Jinquan Cai 1,6,*, Chuanbao Zhang 2,3,*, Wei Zhang 2,3, Guangzhi Wang 1,6, Kun
More informationMutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
DOI 10.1007/s00401-010-0770-2 ORIGINAL PAPER Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology David
More informationYoshinobu Takahashi 1,2*, Hideo Nakamura 1, Keishi Makino 1, Takuichiro Hide 1, Daisuke Muta 1, Hajime Kamada 2 and Jun-ichi Kuratsu 1
Takahashi et al. World Journal of Surgical Oncology 2013, 11:284 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Prognostic value of isocitrate dehydrogenase 1, O 6 -methylguanine-dna methyltransferase
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationPatient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice
Bull Math Biol (2015) 77:846 856 DOI 10.1007/s11538-015-0067-7 REVIEW PAPER Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice
More informationAdult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Adult IDH wild type astrocytomas biologically and clinically resolve into
More informationRelated Policies None
Medical Policy MP 2.04.113 BCBSA Ref. Policy: 2.04.113 Last Review: 05/30/2018 Effective Date: 05/30/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More information2017 Diagnostic Slide Session Case 3
2017 Diagnostic Slide Session Case 3 Andrew Gao, MD Lili-Naz Hazrati, MD, PhD Cynthia Hawkins, MD, PhD Hospital for Sick Children and University of Toronto, Toronto, Canada Disclosures: none Clinical History
More informationIsocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms
ONCOLOGY LETTERS 7: 1895-1902, 2014 Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms SONGTAO QI 1*, LEI YU 1*,
More informationExploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation
European Review for Medical and Pharmacological Sciences Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation H.-C. LU 1, J. MA 2, Z. ZHUANG 1, F.
More informationDetection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
/, Advance Publications 2016 Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas Jinquan Cai 1,7,*, Ping Zhu 4,*, Chuanbao Zhang 2,3,7,*, Qingbin Li 1,7, Zhiliang
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationDysembryoplastic neuroepithelial tumor is a benign,
J Neurosurg Pediatrics 11:518 525, 2013 AANS, 2013 Dynamic changes in magnetic resonance imaging appearance of dysembryoplastic neuroepithelial tumor with or without malignant transformation Report of
More informationGliomatosis cerebri: no evidence for a separate brain tumor entity
DOI 10.1007/s00401-015-1495-z ORIGINAL PAPER Gliomatosis cerebri: no evidence for a separate brain tumor entity Ulrich Herrlinger 1 David T. W. Jones 2,3 Martin Glas 1,4 Elke Hattingen 5 Dorothee Gramatzki
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationIncreased Inhibitor of Differentiation 4 (Id4) Expression in Glioblastoma: A Tissue Microarray Study
1 Research Paper Journal of Cancer 2010; 1:1-5 Ivyspring International Publisher. All rights reserved Increased Inhibitor of Differentiation 4 (Id4) Expression in Glioblastoma: A Tissue Microarray Study
More informationMutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
/, Vol. 5, No. 6 Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas Patrick J. Killela 1,*, Christopher J. Pirozzi 1,*, Patrick Healy 2, Zachary
More informationAnaplastic Pilocytic Astrocytoma: The fusion of good and bad
Anaplastic Pilocytic Astrocytoma: The fusion of good and bad Alexandrina Nikova 1, Charalampos-Chrysovalantis Chytoudis-Peroudis 2, Penelope Korkolopoulou 3 and Dimitrios Kanakis 4 Abstract 5 Pilocytic
More informationAnnouncing cimpact-now: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Announcing cimpact-now: the Consortium to Inform Molecular and Practical
More informationImmunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
DOI 10.1007/s11060-012-0837-0 LABORATORY INVESTIGATION Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors Shingo Takano Yukinari Kato Tetsuya Yamamoto
More informationRapid BRAF mutation detection in melanoma patients by immunohistochemistry
http://dx.doi.org/10.17202/juso.2017.4.1 Journal of Universal Science Vol 4(1): 1-5, 2017 Rapid BRAF mutation detection in melanoma patients by immunohistochemistry László FÜLÖP 1, Katalin GÖTZER 1, Erzsébet
More informationONCOLOGY LETTERS 15: , 2018
ONCOLOGY LETTERS 15: 1459-1468, 2018 Altered capicua transcriptional repressor gene expression exhibits distinct prognostic value for isocitrate dehydrogenase mutant oligodendroglial tumors FUXIN HAN 1*,
More informationMolecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade
J Neuropathol Exp Neurol Copyright Ó 2015 by the American Association of Neuropathologists, Inc. Vol. 74, No. 3 March 2015 pp. 241Y249 ORIGINAL ARTICLE Molecular Classification Defines 4 Prognostically
More informationEfficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis
Efficacy of Treatment for Glioblastoma Multiforme in Elderly Patients (65+): A Retrospective Analysis Igal Kushnir MD 1 * and Tzahala Tzuk-Shina MD 2 1 Oncology Insitute, Tel Aviv Sourasky Medical Center,
More informationGliomatosis cerebri: no evidence for a separate brain tumor entity
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Gliomatosis cerebri: no evidence for a separate brain tumor entity Herrlinger,
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationAssociation of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors
RESEARCH ARTICLE Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors Abdul Aziz Mohamed Yusoff 1 *, Fatin Najwa Zulfakhar 2, Mohd Dasuki Sul ain 2, Zamzuri Idris
More informationLow grade glioma: a journey towards a cure
Editorial Page 1 of 5 Low grade glioma: a journey towards a cure Ali K. Choucair SIU School of Medicine, Springfield, IL, USA Correspondence to: Ali K. Choucair, MD. Professor of Neurology, Director of
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationInt J Clin Exp Med 2017;10(4): /ISSN: /IJCEM Wei Wei *, Yuan Jia *, Chen Hui
Int J Clin Exp Med 2017;10(4):6810-6818 www.ijcem.com /ISSN:1940-5901/IJCEM0043765 Original Article Radiotherapy plus procarbazine, lomustine, and vincristine versus radiotherapy alone for glioma: a meta-analysis
More informationZurich Open Repository and Archive. Procarbazine and CCNU as initial treatment in gliomatosis cerebri
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Procarbazine and CCNU as initial treatment in gliomatosis cerebri Glas, M;
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationAccepted: 13 June 2018
Received: 26 February 2018 Revised: 12 June 2018 DOI: 10.1002/cam4.1666 Accepted: 13 June 2018 ORIGINAL RESEARCH The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized
More informationMutations in isocitrate dehydrogenase 1 (IDH1) exist in a large
ORIGINAL RESEARCH BRAIN Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases W.L. Tan, W.Y. Huang, B. Yin, J. Xiong, J.S. Wu, and D.Y.
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationRelationship of P53 Protein With Histopathology Degree of Intracranial Astrocytoma at Haji Adam Malik Hospital Medan
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.10 No.15, pp 300-304, 2017 Relationship of P53 Protein With Histopathology Degree of Intracranial
More informationNeuro-Oncology Practice
Neuro-Oncology Practice Neuro-Oncology Practice 3(2), 71 76, 2016 doi:10.1093/nop/npv043 Advance Access date 16 October 2015 Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma:
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationSupplementary Online Content
Supplementary Online Content Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationThe 2016 WHO classification of central nervous system tumors: what neurologists need to know
REVIEW C URRENT OPINION The 2016 WHO classification of central nervous system tumors: what neurologists need to know John C. DeWitt a,, Andreas Mock a,b,c,, and David N. Louis a Purpose of review The 2016
More informationBcl-2 and p53 protein expression in all grades of astrocytomas
Southern Adventist Univeristy KnowledgeExchange@Southern Senior Research Projects Southern Scholars 11-1994 Bcl-2 and p53 protein expression in all grades of astrocytomas Robyn L. Castleberg Follow this
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationConcepts for a personalized neurosurgical oncology. XXIV Annual Conference Pietro Paoletti 27. November 2015
Concepts for a personalized neurosurgical oncology Jörg-Christian Tonn Dept. of Neurosurgery Ludwig-Maximilian University München Großhadern Germany XXIV Annual Conference Pietro Paoletti 27. November
More informationWhat yield in the last decade about Molecular Diagnostics in Neuro
What yield in the last decade about Molecular Diagnostics in Neuro Oncology? Raphael Salles S.Medeiros Neuropathologist at HC FMUSP Clinical Research Project Manager at Oncology department at Hospital
More informationBRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER
BRAIN TUMOURS: SUCCESSES AND CHALLENGES ON THE OTHER SIDE OF THE BLOOD-BRAIN BARRIER Kathryn M Field and Mark A Rosenthal Department of Medical Oncology, Royal Melbourne Hospital, Victoria, Australia.
More informationEpidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis
Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,
More informationCDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas
JBUON 213; 18(4): 16-111 ISSN: 117-625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationOriginal Article Immunostaining of IDH-1 R132H and ATRX proteins in the classification of adult glioblastomas
Int J Clin Exp Pathol 2016;9(12):12849-12854 www.ijcep.com /ISSN:1936-2625/IJCEP0038759 Original Article Immunostaining of IDH-1 R132H and ATRX proteins in the classification of adult glioblastomas Ning
More informationNeuropathology Evening Session: Case 3
Neuropathology Evening Session: Case 3 Christine E. Fuller, MD Cincinnati Children s Hospital Medical Center Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position
More information